Impact Factor 3.519

Frontiers journals are at the top of citation and impact metrics

This article is part of the Research Topic

Cross Talk Between The Immune System and Metabolism

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Endocrinol. | doi: 10.3389/fendo.2018.00630

Sodium butyrate ameliorates streptozotocin-induced type 1 diabetes in mice by inhibiting the HMGB1 expression

Yu Guo1, Zheng Xiao1, Yanan Wang1, Weihua Yao1, Shun Liao1, Bo Yu1,  Jianqaing Zhang1,  Bing Zheng1*,  Ren Boxu1* and Gong Quan1*
  • 1Yangtze University, China

Type 1 diabetes (T1D) is an autoimmune disease characterized by the immune cell-mediated progressive destruction of pancreatic -cells. High-mobility group box 1 protein (HMGB1) has been recognized as a potential immune mediator to enhance the development of T1D. So we speculated that HMGB1 inhibitors could have anti-diabetic effect. Sodium butyrate is a short fatty acid derivative possessing anti-inflammatory activity by inhibiting HMGB1. In the current study, we evaluated the effects of sodium butyrate in streptozotocin (STZ)-induced T1D mice model. Diabetes was induced by multiple low-dose injections of STZ (40mg/kg/day for 5 consecutive days), and then sodium butyrate (500mg/kg/day) was administered by intraperitoneal injection for 7 consecutive days after STZ treatment. Blood glucose, incidence of diabetes, body weight, pancreatic histopathology, the amounts of CD4+T cell subsets, IL-1β level in serum and pancreatic expressions levels of HMGB1 and NF-κB p65 protein were analyzed. The results showed that sodium butyrate treatment decreased blood glucose and serum IL-1β, improved the islet morphology and decreased inflammatory cell infiltration, restored the unbalanced Th1/Th2 ratio, and down-regulated Th17 to normal level. In addition, sodium butyrate treatment can inhibit the pancreatic HMGB1 and NF-κB p65 protein expression. Therefore, we proposed that sodium butyrate should ameliorate STZ-induced T1D by down-regulating NF-κB mediated inflammatory signal pathway through inhibiting HMGB1.

Keywords: sodium butyrate, HMGB1, Th1/ Th2, type 1 diabetes, Streptozotocin

Received: 04 Aug 2018; Accepted: 04 Oct 2018.

Edited by:

Jie Chen, Xiamen University, China

Reviewed by:

Hsien-Hui Chung, National Cheng Kung University, Taiwan
Sonia Liao, University of Electronic Science and Technology of China, China  

Copyright: © 2018 Guo, Xiao, Wang, Yao, Liao, Yu, Zhang, Zheng, Boxu and Quan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence:
PhD. Bing Zheng, Yangtze University, Jingzhou, China,
Prof. Ren Boxu, Yangtze University, Jingzhou, China,
Prof. Gong Quan, Yangtze University, Jingzhou, China,